These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 36552849)

  • 101. Efficient chimeric antigen receptor targeting of a central epitope of CD22.
    Casey NP; Klee CH; Fåne A; Caulier B; Graczyk-Jarzynka A; Krawczyk M; Fidyt K; Josefsson SE; Köksal H; Dillard P; Patkowska E; Firczuk M; Smeland EB; Winiarska M; Myklebust JH; Inderberg EM; Wälchli S
    J Biol Chem; 2023 Jul; 299(7):104883. PubMed ID: 37269947
    [TBL] [Abstract][Full Text] [Related]  

  • 102. CD22-targeted CAR T cells induce remission in B-ALL that is naive or resistant to CD19-targeted CAR immunotherapy.
    Fry TJ; Shah NN; Orentas RJ; Stetler-Stevenson M; Yuan CM; Ramakrishna S; Wolters P; Martin S; Delbrook C; Yates B; Shalabi H; Fountaine TJ; Shern JF; Majzner RG; Stroncek DF; Sabatino M; Feng Y; Dimitrov DS; Zhang L; Nguyen S; Qin H; Dropulic B; Lee DW; Mackall CL
    Nat Med; 2018 Jan; 24(1):20-28. PubMed ID: 29155426
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Efficacy and safety of chimeric antigen receptor T cell immunotherapy in B-cell non-Hodgkin lymphoma: a systematic review and meta-analysis.
    Wang N; Meng Y; Wu Y; He J; Liu F
    Immunotherapy; 2021 Mar; 13(4):345-357. PubMed ID: 33406914
    [No Abstract]   [Full Text] [Related]  

  • 105. Imaging Biomarkers to Predict Outcomes in Patients With Large B-Cell Lymphoma With a Day 28 Partial Response by
    Lutfi F; Goloubeva O; Kowatli A; Gryaznov A; Kim DW; Dureja R; Margiotta P; Matsumoto LR; Bukhari A; Ahmed N; Mushtaq MU; Law JY; Lee ST; Kocoglu MH; Atanackovic D; Yared JA; Hardy NM; McGuirk JP; Rapoport AP; Chen W; Dahiya S
    Clin Lymphoma Myeloma Leuk; 2023 Oct; 23(10):757-763. PubMed ID: 37453865
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Predictive short/long-term efficacy biomarkers and resistance mechanisms of CD19-directed CAR-T immunotherapy in relapsed/refractory B-cell lymphomas.
    Xu H; Li N; Wang G; Cao Y
    Front Immunol; 2023; 14():1110028. PubMed ID: 37051246
    [TBL] [Abstract][Full Text] [Related]  

  • 107. Multispecific CAR T Cells Deprive Lymphomas of Escape via Antigen Loss.
    Furqan F; Shah NN
    Annu Rev Med; 2023 Jan; 74():279-291. PubMed ID: 36332638
    [TBL] [Abstract][Full Text] [Related]  

  • 108. A Prospective Investigation of Bispecific CD19/22 CAR T Cell Therapy in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma.
    Zhang Y; Li J; Lou X; Chen X; Yu Z; Kang L; Chen J; Zhou J; Zong X; Yang Z; Li M; Xu N; Jia S; Geng H; Chen G; Dai H; Tang X; Yu L; Wu D; Li C
    Front Oncol; 2021; 11():664421. PubMed ID: 34113569
    [TBL] [Abstract][Full Text] [Related]  

  • 109. Preferential expansion of CD8+ CD19-CAR T cells postinfusion and the role of disease burden on outcome in pediatric B-ALL.
    Talleur AC; Qudeimat A; Métais JY; Langfitt D; Mamcarz E; Crawford JC; Huang S; Cheng C; Hurley C; Madden R; Sharma A; Suliman A; Srinivasan A; Velasquez MP; Obeng EA; Willis C; Akel S; Karol SE; Inaba H; Bragg A; Zheng W; Zhou SM; Schell S; Tuggle-Brown M; Cullins D; Patil SL; Li Y; Thomas PG; Zebley C; Youngblood B; Pui CH; Lockey T; Geiger TL; Meagher MM; Triplett BM; Gottschalk S
    Blood Adv; 2022 Nov; 6(21):5737-5749. PubMed ID: 35446934
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.
    Levin A; Shah NN
    Am J Hematol; 2019 May; 94(S1):S18-S23. PubMed ID: 30652353
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Long-Term Follow-Up of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy.
    Cappell KM; Sherry RM; Yang JC; Goff SL; Vanasse DA; McIntyre L; Rosenberg SA; Kochenderfer JN
    J Clin Oncol; 2020 Nov; 38(32):3805-3815. PubMed ID: 33021872
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Anti-CD19 chimeric antigen receptor T-cell therapy in acute lymphocytic leukaemia: a systematic review and meta-analysis.
    Anagnostou T; Riaz IB; Hashmi SK; Murad MH; Kenderian SS
    Lancet Haematol; 2020 Nov; 7(11):e816-e826. PubMed ID: 33091355
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Long-Term Follow-Up of Combination of B-Cell Maturation Antigen and CD19 Chimeric Antigen Receptor T Cells in Multiple Myeloma.
    Wang Y; Cao J; Gu W; Shi M; Lan J; Yan Z; Jin L; Xia J; Ma S; Liu Y; Li H; Pan B; Chen W; Fei X; Wang C; Xie X; Yu L; Wang G; Li H; Jing G; Cheng H; Zhu F; Sun H; Sang W; Li D; Li Z; Zheng J; Xu K
    J Clin Oncol; 2022 Jul; 40(20):2246-2256. PubMed ID: 35333600
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Cytokine release syndrome and relevant factors of CD19 targeted chimeric antigen receptor T cell therapy in relapsed/refractory B cell hematological malignancies.
    Xu QW; Xu H; Xue L; Wang L; Zhang XH; Song KD; Yao W; Wan X; Tong J; Liu HL; Liu X; Zhu XY; Sun ZM; Wang XB
    Transfus Apher Sci; 2022 Dec; 61(6):103473. PubMed ID: 35672235
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Anti-CD19 chimeric antigen receptor-modified T cells for B-cell malignancies: a systematic review of efficacy and safety in clinical trials.
    Zhu Y; Tan Y; Ou R; Zhong Q; Zheng L; Du Y; Zhang Q; Huang J
    Eur J Haematol; 2016 Apr; 96(4):389-96. PubMed ID: 26115358
    [TBL] [Abstract][Full Text] [Related]  

  • 116. Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.
    Abramson JS
    Transfus Med Rev; 2020 Jan; 34(1):29-33. PubMed ID: 31677848
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Efficacy and safety of CD19 chimeric antigen receptor T cells in the treatment of 11 patients with relapsed/refractory B-cell lymphoma: a single-center study.
    Huang C; Wu L; Liu R; Li W; Li Z; Li J; Liu L; Shan B
    Ann Transl Med; 2020 Sep; 8(17):1048. PubMed ID: 33145267
    [TBL] [Abstract][Full Text] [Related]  

  • 118. Anti-PD-1 Therapy Enhances the Efficacy of CD30-Directed Chimeric Antigen Receptor T Cell Therapy in Patients With Relapsed/Refractory CD30+ Lymphoma.
    Sang W; Wang X; Geng H; Li T; Li D; Zhang B; Zhou Y; Song X; Sun C; Yan D; Li D; Li Z; Li C; Xu K
    Front Immunol; 2022; 13():858021. PubMed ID: 35432352
    [TBL] [Abstract][Full Text] [Related]  

  • 119. The academic point-of-care anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel (ARI-0001 cells) shows efficacy and safety in the treatment of relapsed/refractory B-cell non-Hodgkin lymphoma.
    Martínez-Cibrián N; Ortiz-Maldonado V; Español-Rego M; Blázquez A; Cid J; Lozano M; Magnano L; Giné E; Correa JG; Mozas P; Rodríguez-Lobato LG; Rivero A; Montoro-Lorite M; Ayora P; Navarro S; Alserawan L; González-Navarro EA; Castellà M; Sánchez-Castañón M; Cabezón R; Benítez-Ribas D; Setoaín X; Rodríguez S; Brillembourg H; Varea S; Olesti E; Guillén E; Sáez-Peñataro J; de Larrea CF; López-Guillermo A; Pascal M; Urbano-Ispizua Á; Juan M; Delgado J
    Br J Haematol; 2024 Feb; 204(2):525-533. PubMed ID: 37905734
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Novel CD19-specific γ/δ TCR-T cells in relapsed or refractory diffuse large B-cell lymphoma.
    Li C; Zhou F; Wang J; Chang Q; Du M; Luo W; Zhang Y; Xu J; Tang L; Jiang H; Liu L; Kou H; Lu C; Liao D; Wu J; Wei Q; Ke S; Deng J; Liu C; Mei H; Hu Y
    J Hematol Oncol; 2023 Jan; 16(1):5. PubMed ID: 36681817
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.